We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
UK-based life sciences firm Juvenescence has announced a $100m series B financing round to support the development of artificial intelligence (AI)-based therapeutics and technologies for ageing diseases.